FCE7: Findings of the Best Evidence Consensus on Biologics

Speakers

The AAP recently completed a Best Evidence Consensus (BEC) meeting on the use of biologics in contemporary periodontal practice. The goal of this BEC was to provide an updated perspective on the therapeutic use of autologous-blood derived products (ABPs), enamel matrix derivatives (EMD), platelet-derived growth factor-BB (PDGF-BB), and bone morphogenetic protein 2 (BMP-2) for the treatment of mucogingival deformities and periodontal infrabony defects, and for alveolar ridge preservation and implant site development. This session is aimed at providing an overview of the main findings of three comprehensive literature reviews and the actual expert consensus. This information can help with clinical decision making and treatment planning involving the use of biologics in daily practice.

Educational Objectives:
•    Identify the clinical indications of different biologics currently available for use in clinical practice.
•    Know the evidence supporting the use of biologics for the treatment of mucogingival deformities and periodontal infrabony defects, and for alveolar ridge preservation and implant site development.
•    Recognize the benefits, limitations, and potential risks associated with the use of biologics in periodontal practice.